Lymphoplasmacytic lymphoma screening: Difference between revisions
Sara Mohsin (talk | contribs) No edit summary |
Sara Mohsin (talk | contribs) |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}}{{S.M.}} | {{CMG}}; {{AE}}{{S.M.}} | ||
==Overview== | ==Overview== | ||
According to the the U.S. Preventive Service Task Force ([[United states preventive services task force recommendations scheme|USPSTF]]), there is insufficient evidence to recommend routine [[screening]] for | According to the the U.S. Preventive Service Task Force ([[United states preventive services task force recommendations scheme|USPSTF]]), there is insufficient evidence to recommend routine [[screening]] for lymphoplasmacytic lymphoma. | ||
==Screening== | ==Screening== | ||
Revision as of 17:00, 18 February 2019
|
Lymphoplasmacytic lymphoma Microchapters |
|
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Lymphoplasmacytic lymphoma screening On the Web |
|
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma screening |
|
Risk calculators and risk factors for Lymphoplasmacytic lymphoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for lymphoplasmacytic lymphoma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for Waldenström macroglobulinemia.[1]
References
- ↑ Recommendations. US preventive services task force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=waldenstrom+macroglobulinemia Accessed on November 10, 2015